Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers
Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized, 3-way crossover study. Each subject will
receive each of the three study treatments once, followed by in-clinic monitoring and
extensive blood sample collection for plasma PK analysis.
Dosing will occur at least 48 hours apart from the time of patch application, until
completion of dosing in randomized order per the treatment sequence schedule. After
completion dosing, subjects will be assessed one final time.